Enliven Therapeutics (NASDAQ:ELVN) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Enliven Therapeutics from sell to hold, adding to a generally positive analyst tone around the stock.
• Several firms raised their price targets, including HC Wainwright to $56, Goldman Sachs to $59, and Mizuho to $45. Overall, the stock now has a Moderate Buy consensus and an average target price of $47.80.
• Enliven Therapeutics reported a quarterly loss of $0.38 per share, beating expectations of -$0.44. The stock closed around $40.75 and has traded between $14.78 and $48.53 over the past year.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Monday.

A number of other analysts have also weighed in on the company. HC Wainwright increased their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. The Goldman Sachs Group increased their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a "buy" rating in a research note on Friday. Mizuho increased their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Enliven Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $47.80.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $40.75 on Monday. The company has a market cap of $2.48 billion, a PE ratio of -24.40 and a beta of 0.32. The business has a fifty day moving average of $37.05 and a 200 day moving average of $27.33. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. As a group, research analysts anticipate that Enliven Therapeutics will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Richard A. Heyman sold 1,230 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Benjamin Hohl sold 10,000 shares of the firm's stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in ELVN. KBC Group NV purchased a new position in shares of Enliven Therapeutics during the first quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after buying an additional 594 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after buying an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at $83,000. Finally, Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after buying an additional 1,434 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.